Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Treating S. Aureus in Atopic Dermatitis
NCT00179959Phase 4Completed
- Sponsor
- Northwestern University
- Start
- Sep 2005
- Primary completion
- Mar 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of mupirocin and sodium hypochlorite in atopic dermatitis (AD) (2 arms), sponsored by Northwestern University. Primary endpoint: Change in Eczema Area and Severity Index Scores at 3 months. Started Sep 2005; status: completed.
02
Drugs
mupirocinsodium hypochlorite
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00179959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179959.